Our strategies are designed to make HIV, TB and Hepatitis C medicines more affordable.
We believe that a sustainable response to these epidemics cannot be achieved without tackling the overpricing of medicines.
To do this we need increased competition, fair pricing and increased access. Innovation in medicine is only valuable if it reaches the people who need it.
On the pages below we briefly outline the specific strategies that civil society and governments can employ to remove intellectual property (IP) barriers to treatment.
Our work involves working closely with government ministries and patent offices; providing information to global development agencies and donors on where their investment will have the most impact; and advocating for the pharmaceutical industry to deliver fair pricing and ensure their access strategies are informed by communities.
Civil society organizations implement our work in middle-income countries, which have a dual burden of high prevalence and high prices. We support organizations so they are equipped to challenge IP barriers in their country/region.
We monitor trade negotiations, and challenge attempts to protect intellectual property at the expense of public health.
Law and policy reform
We advocate for change in laws and policies to protect access to medicines and public health.
We challenge applications for unmerited patents on antiretroviral drugs to force companies to compete and reduce the price of their drugs.
We encourage governments to fully exercise their right to suspend patent protection, when it threatens access to medicines.